Analysts forecast that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will announce ($0.51) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Syros Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.63) and the highest is ($0.46). Syros Pharmaceuticals posted earnings of ($0.47) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 8.5%. The company is expected to issue its next earnings report on Thursday, November 7th.
On average, analysts expect that Syros Pharmaceuticals will report full-year earnings of ($1.94) per share for the current fiscal year, with EPS estimates ranging from ($2.07) to ($1.84). For the next fiscal year, analysts expect that the company will post earnings of ($1.97) per share, with EPS estimates ranging from ($2.34) to ($1.68). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.06). Syros Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 3,137.55%. The firm had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.42 million.
SYRS has been the subject of a number of recent research reports. HC Wainwright reaffirmed a “neutral” rating on shares of Syros Pharmaceuticals in a research note on Thursday, May 2nd. Zacks Investment Research downgraded Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. ValuEngine raised Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, June 26th. BidaskClub raised Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, July 12th. Finally, Wedbush reaffirmed an “outperform” rating and set a $13.00 price target on shares of Syros Pharmaceuticals in a research note on Thursday, April 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $16.03.
In other news, major shareholder Venture Fund Vii L.P. Arch sold 63,000 shares of the stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $7.77, for a total transaction of $489,510.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 14.80% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of SYRS. BlackRock Inc. grew its holdings in Syros Pharmaceuticals by 23.1% in the 4th quarter. BlackRock Inc. now owns 1,986,130 shares of the company’s stock valued at $11,063,000 after buying an additional 372,462 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Syros Pharmaceuticals by 8.9% in the 4th quarter. Bank of New York Mellon Corp now owns 84,537 shares of the company’s stock valued at $470,000 after buying an additional 6,883 shares during the last quarter. Northern Trust Corp grew its holdings in Syros Pharmaceuticals by 0.7% in the 4th quarter. Northern Trust Corp now owns 306,167 shares of the company’s stock valued at $1,705,000 after buying an additional 2,179 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Syros Pharmaceuticals by 62.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 244,080 shares of the company’s stock valued at $1,360,000 after buying an additional 93,728 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Syros Pharmaceuticals by 10.3% in the 4th quarter. Geode Capital Management LLC now owns 249,668 shares of the company’s stock worth $1,390,000 after acquiring an additional 23,234 shares during the period. 65.27% of the stock is currently owned by institutional investors and hedge funds.
Shares of SYRS traded up $1.23 during midday trading on Friday, reaching $11.08. 312,600 shares of the stock were exchanged, compared to its average volume of 179,558. Syros Pharmaceuticals has a 12-month low of $5.17 and a 12-month high of $13.16. The firm has a 50 day simple moving average of $8.25 and a 200-day simple moving average of $7.35. The company has a quick ratio of 8.11, a current ratio of 8.11 and a debt-to-equity ratio of 0.15. The company has a market cap of $372.18 million, a price-to-earnings ratio of -5.80 and a beta of 1.94.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Featured Article: Capital gains and your 401(k) or IRA
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.